First-line therapy with bortezomib (formerly PS-341) in patients with multiple myeloma (MM).
S. Jagannath,B. Durie,J. Wolf,E. Camacho,D. Irwin,J. Lutzky,M. McKinley,E. Gabayan,J. Crowley,D. Schenkein
DOI: https://doi.org/10.1200/JCO.2004.22.90140.6551
IF: 45.3
2004-07-15
Journal of Clinical Oncology
Abstract:6551 Background: Preclinical evidence has suggested that the proteasome is an effective therapeutic target in MM. Clinical trials have since demonstrated the durable efficacy and safety of bortezomib (Velcade), a potent reversible proteasome inhibitor, recently approved for the treatment of pts with refractory and relapsed MM. Preliminary results of an ongoing phase 2 trial of bortezomib administered to pts with newly diagnosed MM are reported here.
METHODS
Pts received bortezomib 1.3 mg/m2 2x/wk x2 q3 wk for a maximum of 6 cycles. Dexamethasone 40 mg the day of and after each bortezomib dose was allowed after 2 cycles for pts with < PR, and after 4 cycles for pts with < CR. Response criteria were based on modified EBMT criteria, with the addition of a near CR category (disappearance of all M protein by electrophoresis, but positive immunofixation, with normal bone marrow). Stem cells could be harvested at the discretion of the physician. Neurologic tests are being performed before and after bortezomib.
RESULTS
Nineteen pts (47% males, median age 63 yrs) have been accrued. Pts presented with IgG (58%), IgA (32%), or light chain (10%) disease, with a median KPS of 90 (50 - 100). The majority of pts were Durie-Salmon Stage III (55%). As of November 2003, 12 pts have completed 6 cycles and were evaluable for response: there were 4 (33%) near CR, 5 (42%) PR, 1 (8%) MR, and 2 (17%) PD. One pt has undergone stem cell transplant with complete hematologic recovery. The most common adverse events (grades 1 -3) were fatigue (67%), diarrhea (58%), constipation (42%), nausea (42%), peripheral neuropathy (33%), and vomiting (33%). One episode of each of the following grade 3 events occurred: abdominal pain, diarrhea, dizziness, dyspnea, fever, neuropathic pain, neutropenia, syncope, and vomiting. One pt required dose modification. No grade 4 toxicity was observed.
CONCLUSIONS
In this study, bortezomib appeared to be promising as initial therapy in patients with newly diagnosed MM and had manageable toxicities. Major responses (near CR and PR) were seen in 75% of the patients by 6 cycles. Study accrual is ongoing, and the full complement of 42 pts is expected to be recruited quickly. [Table: see text].